http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
HCC : PE-040 ; The optimal cutoff level of serum AFP for HCC screening in patients taking entecavir
( Chang Hyeon Seock ),( Han Chu Lee ),( Young Hwa Chung ),( Yung Sang Lee ),( Young Suk Lim ),( Kang Mo Kim ),( Ju Hyun Shim ),( Dan Bi Lee ),( Jang Won Park ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.-
Background: The cut-off value of alpha-feto protein(AFP) has been used for hepatocellular carcinoma(HCC) detection, although serum AFP level is not a good indicator. In patients taking entecavir(ETV) for chronic hepatitis B, serum AFP level seems to be lower than that of the patients not taking ETV. So, it can be supposed that the cut-off value of serum AFP for detecting HCC will be lower in the patients taking ETV. Method: There were 30 HCC cases that had taken ETV for treatment of chronic hepatitis B for 6 months or more. We used 207 non-HCC patients who had been on ETV as control group. The AFP level of control group was the highest level after 1 year taking entecavir. In each group, receiver operating characteristic (ROC) curves were compared to determine the optimal cut-off value for diagnosis of HCC. Result: The average duration of taking entecavir in case group is 731.5 days and the mean level of AFP level of HCC cases was 127.9 ng/mL. But in only 5 cases, AFP level was higher than 200 ng/mL. The optimal AFP cut-off value 8.6ng/mL, at which point the sensitivity and specificity was 63.3% and 96.1% respectively. The area under curve was 0.827. Conclusion: In this study, the best discriminating AFP value for HCC detection in patients taking entecavir was 8.6 ng/mL, which is much lower than that of those not taking ETV. Therefore, lowering serum AFP cut-off value for patients on ETV should be considered.
HCC : PE-040 ; The optimal cutoff level of serum AFP for HCC screening in patients taking entecavir
( Chang Hyeon Seock ),( Han Chu Lee ),( Young Hwa Chung ),( Yung Sang Lee ),( Young Suk Lim ),( Kang Mo Kim ),( Ju Hyun Shim ),( Dan Bi Lee ),( Ang Won Park ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
Background: The cut-off value of alpha-feto protein(AFP) has been used for hepatocellular carcinoma(HCC) detection, although serum AFP level is not a good indicator. In patients taking entecavir(ETV) for chronic hepatitis B, serum AFP level seems to be lower than that of the patients not taking ETV. So, it can be supposed that the cut-off value of serum AFP for detecting HCC will be lower in the patients taking ETV. Method: There were 30 HCC cases that had taken ETV for treatment of chronic hepatitis B for 6 months or more. We used 207 non-HCC patients who had been on ETV as control group. The AFP level of control group was the highest level after 1 year taking entecavir. In each group, receiver operating characteristic (ROC) curves were compared to determine the optimal cut-off value for diagnosis of HCC. Result: The average duration of taking entecavir in case group is 731.5 days and the mean level of AFP level of HCC cases was 127.9 ng/mL. But in only 5 cases, AFP level was higher than 200 ng/mL. The optimal AFP cut-off value 8.6ng/mL, at which point the sensitivity and specificity was 63.3% and 96.1% respectively. The area under curve was 0.827. Conclusion: In this study, the best discriminating AFP value for HCC detection in patients taking entecavir was 8.6 ng/mL, which is much lower than that of those not taking ETV. Therefore, lowering serum AFP cut-off value for patients on ETV should be considered.
석창현 ( Chang Hyeon Seock ),이단비 ( Dan Bi Lee ),심주현 ( Ju Hyun Shim ),김강모 ( Kang Mo Kim ),임영석 ( Young Suk Lim ),이한주 ( Han Chu Lee ),정영화 ( Young Hwa Chung ),이영상 ( Yung Sang Lee ) 대한간암학회 2012 대한간암학회지 Vol.12 No.1
According to AASLD practice guideline, for patients who present with advanced hepatocelluar carcinoma, new data indicates the efficacy of sorafenib in prolonging life. But there are no data comparing combination transarterial chemoemboliation with sorafenib to sorafenib treatment alone. We experienced a case that treated a patient with combination therapy including transarterial chemoembolization for intrahepatic hepatocelluarcarcinoma, radiation therapy for portal vein thrombosis and sorafenib treatment. He was in stable disease state after 6 months later. Therefore, it seems to be need to study for comparing combination therapy to sorafenib, or to transarterial chemoembolization.
Cisplatin 경동맥화학색전술 후 발생한 용혈성 요독 증후군 1예
석창현 ( Chang Hyeon Seock ),이단비 ( Danbi Lee ),심주현 ( Ju Hyun Shim ),김강모 ( Kang Mo Kim ),임영석 ( Young Suk Lim ),이한주 ( Han Chu Lee ),정영화 ( Young Hwa Chung ),이영상 ( Yung Sang Lee ) 대한간암학회 2012 대한간암학회지 Vol.12 No.2
Hemolytic uremic syndrome (HUS) is a rare condition compromising the clinical triad of acute renal failure, microangiopathic hemolytic anemia, and thrombocytopenia. HUS may be associated with a variety of etiologies, and chemotherapeutic agents have also been reported to be associated with HUS, including mitomycin, cisplatin, bleomycin, and most recently gemcitabine. HUS also has been observed in association with a number of disseminated malignancies in adults, most typically adenocarcinoma of the stomach and breast. But there was no case report of HUS after cisplatin based transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). We experienced a case of HUS after cisplatin based TACE and reported this case with several literature reviews.
( Tae Seob Jung ),( Chang Hyeon Seock ),( In Sun Min ),( Ju Young Lee ),( Shinn Hee Park ),( Hee Jeong Lee ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
A mucin producing appendiceal tumor is very rare. We report a case in a 70-years-old woman, with abdominal pain and distension, who had history of breast cancer. Abdominal computed tomography revealed ascites collection and diffuse engorgement, infi ltration of the mesenteric vessel. Peritonitis or peritoneal carcinomatosis were suspected. So diagnostic paracentesis was tried several times, but proper specimen could not be obtained, because the ascites was thick and gelatinous. Thus, gaining specimens from peritoneum was achieved through diagnostic laparoscopy. But, the surgeon could not fi nd the origin, because of adhesions and large amount of mucoceles. The histologic result indicated pseudomyxoma peritonei. Low-grade appendiceal mucinous neoplasm or mucinous adenocarcinoma were suspected. Colonoscopy was done after 3 weeks and appendiceal tumor was discovered. The patient was treated with fiuorouracil for 6 months like adenocarcinoma. Now she has been followed up for 9 months without recurrence.
α-Galactosylceramide-loaded, antigen-expressing B cells prime a wide spectrum of antitumor immunity
Kim, Yeon-Jeong,Ko, Hyun-Jeong,Kim, Yun-Sun,Kim, Dong-Hyeon,Kang, Seock,Kim, Jong-Mook,Chung, Yeonseok,Kang, Chang-Yuil Wiley Subscription Services, Inc., A Wiley Company 2008 International journal of cancer: Journal internati Vol.122 No.12
<P>Most of the current tumor vaccines successfully elicit strong protection against tumor but offer little therapeutic effect against existing tumors, highlighting the need for a more effective vaccine strategy. Vaccination with tumor antigen-presenting cells can induce antitumor immune responses. We have previously shown that NKT-licensed B cells prime cytotoxic T lymphocytes (CTLs) with epitope peptide and generate prophylactic/therapeutic antitumor effects. To extend our B cell vaccine approach to the whole antigen, and to overcome the MHC restriction, we used a nonreplicating adenovirus to transduce B cells with antigenic gene. Primary B cells transduced with an adenovirus-encoding truncated Her-2/neu (AdHM) efficiently expressed Her-2/neu. Compared with the moderate antitumor activity induced by vaccination with adenovirus-transduced B cells (B/AdHM), vaccination with α-galactosylceramide-loaded B/AdHM (B/AdHM/αGalCer) induced significantly stronger antitumor immunity, especially in the tumor-bearing mice. The depletion study showed that CD4<SUP>+</SUP>, CD8<SUP>+</SUP> and NK cells were all necessary for the therapeutic immunity. Confirming the results of the depletion study, B/AdHM/αGalCer vaccination induced cytotoxic NK cell responses but B/AdHM did not. Vaccination with B/AdHM/αGalCer generated Her-2/neu-specific antibodies more efficiently than B/AdHM immunization. More importantly, B/AdHM/αGalCer could prime Her-2/neu-specific cytotoxic T cells more efficiently and durably than B/AdHM. CD4<SUP>+</SUP> cells appeared to be necessary for the induction of antibody and CTL responses. Our results demonstrate that, with the help of NKT cells, antigen-transduced B cells efficiently induce innate immunity as well as a wide range of adaptive immunity against the tumor, suggesting that they could be used to develop a novel cellular vaccine. © 2008 Wiley-Liss, Inc.</P>
화학수소화합물을 이용한 소형 무인항공기용 연료전지 시스템 연구
홍지석(Ji-Seok Hong),정원철(Won-chul Jung),김현진(Hyeon-jin Kim),이민재(Min-Jae Lee),정대성(Dae-Seong Jeong),전창수(Chang-Soo Jeon),성홍계(Hong-Gye Sung),신석재(Seock-Jae Shin),남석우(Suk-Woo Nam) 한국항공우주학회 2013 韓國航空宇宙學會誌 Vol.41 No.3
소형 무인항공기의 동력장치로 연료전지 시스템을 적용하기 위해 화학수소화합물 수소 저장방법을 이용한 소형 수소 발생 제어장치를 설계하였다. 효율이 높은 소형/경량 수소 발생 제어장치를 설계하기 위하여 NaBH4 수용액 공급 유량에 따른 Co-B 촉매의 수소 전환율을 확인하였고, 100W 스택의 최대 수소 발생량에 적합한 Co-B 촉매양을 제안하였다. 효율적인 연료 소모를 위해 Dead-end 방식의 스택을 선택하였고, 수소 발생 제어장치 내부 압력을 이용한 펌프 on/off 제어로 수소 생성량을 제어하였다. 소형 수소 발생 제어장치를 이용한 연료전지 시스템의 각 작동구간에서 안정된 운전을 확인하였다. 장시간 운전 실험을 통하여 최대 7시간 운전이 가능하며, 임의의 비행 프로화일에 요구되는 추력 프로화일은 최소 4시간 이상 조정 가능함을 확인하였다. A compact hydrogen generation device of fuel cell system using chemical hydride storage technique was designed to fit the propulsion device requirement of a small unmanned aerial vehicle(SUAV). For high efficient, compact, and lightweight hydrogen generation control device, the Co-B catalyst hydrogen conversion rate by NaBH4 aqueous solution flux is measured so that the proper amount of Co-B catalyst for maximum hydrogen generation of 100W stack was proposed. A compact hydrogen generation device is controlled by pumps on/off using its own internal pressure and consumes fuel in high efficiency through a dead-end type fuel cell. The fuel cell system has stable operation for a planed flight profile. The system operates up to maximum 7 hours and at least 4 hours for tough flight profiles.
정태섭 ( Tae Seob Jung ),홍정운 ( Jung Un Hong ),박신희 ( Shin Hee Park ),이희정 ( Hee Jeong Lee ),민인선 ( In Sun Min ),이주영 ( Ju Young Lee ),석창현 ( Chang Hyeon Seock ) 대한소화기학회 2016 대한소화기학회지 Vol.67 No.3
Pseudomyxoma peritonei is a very rare condition, and even rarer in patients with history of cancer. A 70-year old woman with a history of breast cancer was admitted with abdominal pain and distention. Abdominal computed tomography revealed ascites collection, diffuse engorgement and infiltration of the mesenteric vessel, suggesting peritonitis or peritoneal carcinomatosis. Diagnostic paracentesis was attempted several times, but a sufficient specimen could not be collected due to the thick and gelatinous nature of the ascites. Therefore, the patient underwent diagnostic laparoscopy for tissue biopsy of the peritoneum, which indicated pseudomyxoma peritonei. However, the origin of the pseudomyxoma peritonei could not be identified intraoperatively due to adhesions and large amount of mucoceles. Systemic chemotherapy was performed using Fluorouracil, producing some symptomatic relief. After discharge, abdominal pain and distention gradually worsened, so at 18 months after initial diagnosis the patient received palliative surgery based on massive mucinous ascites and palpable mass at the omentum. The patient expired after surgery due to massive bleeding. (Korean J Gastroenterol 2016;67:153-157)
자연 용해된 급성 췌장염에 동반된 고립성 상장간막정맥 혈전증
나병수 ( Byung Soo Na ),전병민 ( Byung Min John ),김기범 ( Ki Bum Kim ),이제수 ( Je Soo Lee ),조현우 ( Hyun Woo Jo ),석창현 ( Chang Hyeon Seock ),김동휘 ( Dong Hui Kim ),이기성 ( Ki Sung Lee ) 대한소화기학회 2011 대한소화기학회지 Vol.57 No.1
Acute pancreatitis can result in many vascular complications in both artery and vein. Venous complication usually occurs as a form of splenic or portal vein thrombosis, and also can simultaneously occur in superior mesenteric vein as well. Rarely, isolated superior mesenteric vein thrombosis occurs as a venous complication. Although it is uncommon, mesenteric vein thrombosis is an important clinical entity because of the possibility of mesenteric ischemia and infarction of small bowel. The treatments of mesenteric venous thrombosis include anticoagulation therapy, transcatheter therapy and surgical intervention. We report a case of 45-yearold man who had acute pancreatitis with isolated superior mesenteric vein thrombosis, which was spontaneously dissolved with the resolution of underlying inflammation without anticoagulation or surgical intervention. (Korean J Gastroenterol 2011;57:38-41)